Journal
BIOMOLECULES
Volume 11, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/biom11050720
Keywords
schizophrenia; lipid; lipidomics; triglyceride; mass spectrometry; PANSS
Categories
Funding
- Russian Science Foundation [19-74-00151]
- Russian Science Foundation [19-74-00151] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
Changes in certain lipid levels in the blood plasma of schizophrenia patients may be associated with the extent of symptom improvement, with these lipid species characterized by a relatively low number of carbons in their fatty acid residues and relatively low abundance compared to principal triglyceride species in blood plasma.
Schizophrenia is a serious mental disorder requiring lifelong treatment. While medications are available that are effective in treating some patients, individual treatment responses can vary, with some patients exhibiting resistance to one or multiple drugs. Currently, little is known about the causes of the difference in treatment response observed among individuals with schizophrenia, and satisfactory markers of poor response are not available for clinical practice. Here, we studied the changes in the levels of 322 blood plasma lipids between two time points assessed in 92 individuals diagnosed with schizophrenia during their inpatient treatment and their association with the extent of symptom improvement. We found 20 triglyceride species increased in individuals with the least improvement in Positive and Negative Syndrome Scale (PANSS) scores, but not in those with the largest reduction in PANSS scores. These triglyceride species were distinct from the rest of the triglyceride species present in blood plasma. They contained a relatively low number of carbons in their fatty acid residues and were relatively low in abundance compared to the principal triglyceride species of blood plasma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available